Drug Candidates for the Prevention and Treatment of Cardiovascular Diseases
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 July 2022) | Viewed by 56442
Special Issue Editor
Interests: cardiovascular disease prevention; atherosclerotic plaque vulnerability; heart failure
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cardiovascular diseases (CVDs) comprise the first leading cause of morbidity and mortality in the western world. Despite the great advances in pharmaceutical therapy, there is still an increasing need to develop and apply more effective medications for primary and secondary prevention of CVDs. The aim of the present Special Issue is to attract more than 10 high-quality papers that focus on drugs with potentiality to contribute to CVD prevention and treatment. Those drug candidates may be substances that target several aspects of pathophysiological mechanisms of CVDs or may comprise therapeutic regimes of other, non-cardiovascular diseases, with potential expansion of their indications to CVDs. Among all, lipid lowering remains the cornerstone of prevention and treatment of CVDs. Novel, especially gene-oriented, lipid-lowering agents seem quite promising. Medicinal chemistry has introduced technological and conceptual innovations with wide potential application in CVDs. In this context, gene delivery methods may provide an alternative in otherwise untreated CVDs, such as pulmonary hypertension. In parallel, emerging medications in non-CVDs but with established cardiovascular benefits, such as sodium-glucose co-transporter 2 inhibitors with ever expanding use in patients with heart failure or the anti-inflammatory agents and immunomodulators used in auto-immune diseases, have opened a new era in pharmaceutical treatment of patients with CVDs. In addition to this, drugs targeting the main pathophysiological mechanisms of CVDs, such as the inhibition of myocardial fibrosis or cardiovascular inflammatory infiltration, are quite promising as well. Finally, herbal medicine remains a very promising source of drug candidate and requires further investigation. Taken together, there is an increasing burden of drugs that could serve effectively in primary and secondary CVD prevention. A thorough discussion about them should start in order to improve the quality of life of all patients.
Dr. Nikolaos Kadoglou
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lipid lowering
- anti-diabetic drugs
- hypercholesterolemia
- hypertriglyceridemia
- PCSK9
- SGLT-2
- immunomodulators
- gene therapy
- anti-inflammatory drugs
- regenerative medicine
- herbal medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.